Background and Purpose-Moyamoya disease (MMD) is a unique cerebrovascular occlusive disease characterized by progressive stenosis and negative remodeling of the distal internal carotid artery (ICA). We hypothesized that cav-1 (caveolin-1)-a protein that controls the regulation of endothelial vesicular trafficking and signal transduction-is associated with negative remodeling in MMD. Methods-We prospectively recruited 77 consecutive patients with MMD diagnosed via conventional angiography.
M oyamoya disease (MMD) is a unique cerebrovascular occlusive disease that is characterized by progressive stenosis of the distal internal carotid artery (ICA) and a hazy network of basal collaterals. 1, 2 Although recent genetic studies have identified a possible gene for susceptibility to MMD in East Asians, that is, RNF213 gene in the 17q25-ter region, [3] [4] [5] the cause of MMD has not been fully elucidated. 6 In addition to genetic factors, environmental factors and circulating factors related to genetic susceptibility may play important roles in the complex pathogenic mechanisms of MMD. 6 Cav-1 (caveolin-1)-a scaffolding protein component of caveolae plasma membrane domains-plays an important positive role in the regulation of endothelial cell differentiation-a prerequisite step in the process of angiogenesis. 7, 8 Hence, it is possible that cav-1 plays a role in the development and progression of MMD via arterial remodeling in the distal ICA.
Arterial remodeling of the vessel wall at the site of stenosis was studied mostly in patients with coronary artery plaques. 9, 10 Positive (outward) remodeling is defined as the compensatory increase in local vessel size in response to an increasing plaque burden and was associated with unstable plaques. 10, 11 On the contrary, negative (constrictive) remodeling is defined as the
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local shrinkage of vessel size; however, the clinical implication of negative remodeling has seldom been studied. 10 MMD can be characterized by negative remodeling and absence of plaque and be a good candidate model to study the biological implication of the relationship between negative remodeling and clinical presentation.
In the present study, we attempted to explore these hypotheses by investigating the association between the serum cav-1 levels and diameter of the distal ICAs using high-resolution magnetic resonance imaging (HR-MRI) in patients with angiographically confirmed MMD. In addition, the determinants of the degree of negative remodeling in patients with MMD were assessed via an analysis of various potential clinical and genetic factors. Lastly, we investigated the mechanisms of cav-1 underlying negative arterial remodeling through an in vitro study.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Patients
Between January 2012 and May 2015, adult patients diagnosed with MMD in a university medical center were prospectively recruited. The diagnosis of MMD was based on stenosis of the distal ICA or middle cerebral artery and a hazy network of basal collaterals evaluated using conventional angiography. Subjects who underwent HR-MRI, agreed to the use of their serum samples for biomarker examinations, and were tested for RNF213 gene mutation were analyzed. The patients were categorized into unilateral and bilateral MMD groups according to the revised diagnostic criteria for definitive MMD by the Research Committee of MMD of the Japanese Ministry of Health, Labor, and Welfare in 2015. 12 Seventeen age-and sex-matched patients with acute (within 7 days of symptom onset) intracranial atherosclerotic stroke and without the RNF213 gene mutation were examined using HR-MRI and were included in the study as controls. Clinical information, including age, sex, and vascular risk factors, was collected systematically, and all patients underwent routine blood tests. The study participants were classified on the basis of their clinical presentation: asymptomatic (without ischemic/hemorrhagic stroke or transient ischemic attack, ie, headache, dizziness, and syncope), transient ischemic attack, ischemic stroke, and intracerebral hemorrhage. Local institutional review boards approved this study. All patients or their next of kin provided informed consent to their participation in the study.
Blood Biomarkers for Cav-1
The plasma level of cav-1 was quantified using a cav-1 ELISA Kit (catalog No. E0214h; EIAab, Wuhan, China). ELISA was performed in accordance with the manufacturer's instructions. All ELISA absorbance readings were read with reference to the standard curve. All samples were run in duplicate. ELISA plates were read using a SpectraMax 340PC384 Microplate Reader and analyzed using the SoftMax Pro Data Analysis Software (Molecular Devices, Sunnyvale, CA).
Identification of the RNF213 Mutation
Peripheral blood samples were drawn from the patients during admission. Genomic DNA was extracted from peripheral blood leukocytes using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI) according to the manufacturer's instructions. The c.14429G>A (p.Arg4810Lys) mutation of the RNF213 gene (GenBank accession No. NM_001256071.1) was amplified using primer sets designed by the authors (available on request). Polymerase chain reaction was performed using a thermal cycler (model 9700; Applied Biosystems, Foster City, CA) and direct sequencing using a BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) on an ABI Prism 3730xl genetic analyzer (Applied Biosystems) as described in our previous study.
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High-Resolution Magnetic Resonance Imaging
HR-MRI was performed using a 3-Tesla system (Achieva; Philips Medical Systems, Best, the Netherlands) with a standard 8-channel head coil. The neuroradiologist (J.C.) selected the vessel and site of evaluation based on the clinical presentation and 3-dimensional timeof-flight magnetic resonance angiography findings and the combination of acquisition orientations (axial only or axial and sagittal). The details of the HR-MRI protocols were provided elsewhere. 14 The outer vessel diameters were measured on T2/proton density-weighted images using the MIPAV program (Medical Image Processing, Advanced Visualization), by the National Institutes of Health, after gathering Digital Imaging and Communications in Medicine files from the magnetic resonance imaging unit. Previous studies by our team and others have shown that MMD is characterized by a shrinkage of the ICA, regardless of symptoms. 14, 15 The outer ICA diameters were measured on HR-MRI as follows: (1) the distal ICAs immediately after the branching ophthalmic artery were selected for measurement and were marked for repeated measurements; (2) based on the immediate proximal and distal images of the slides used for measurement, the horizontal length on HR-MRI was used to present the distal ICA diameter when it was positioned perpendicularly; otherwise, the vertical length was used; and (3) 2 neurologists blinded to the clinical information interpreted the HR-MRIs independently, and one of them remeasured the images 2 weeks later so that the intraobserver variability could be estimated. In patients with MMD, the ICAs were measured bilaterally. In controls, the outer ICA diameters were measured in both ICAs, and the diameters of the asymptomatic ICA without atherosclerotic plaque were used for the analyses. The intraclass correlation coefficients for the measured HR-MRI parameter were examined for both inter-and intraobserver agreements; in the present study, the coefficients were 0.821 and 0.849, respectively.
Culture of Human Umbilical Vein Endothelial Cells and Coronary Artery Smooth Muscle Cells
Human umbilical vein endothelial cells (HUVECs), coronary artery smooth muscle cells (CASMCs), and each cell culture medium (EGM-2 [endothelial cell growth medium-2] BulletKit and SmGM-2 [smooth muscle cell growth medium-2] BulletKit) were purchased from Lonza (Walkersville, MD). HUVECs were cultured in an EGM-2 complete medium, and CASMCs were cultured in an SmGM-2 complete medium. Both cells were maintained at 37°C in 5% CO 2 atmosphere.
Transfection of Small Interfering RNA and Overexpression Vector
SiRNA oligonucleotides targeting cav-1 3ʹ-UTR (three prime untranslated region) and control small interfering RNA (siRNA) were chemically synthesized by Bioneer Corporation (Daejeon, Korea). The sequence of each siRNA is shown in Table I in the online-only Data Supplement. Transfection of siRNAs was performed using Lipofectamine 2000 (Invitrogen, Grand Island, NY) according to the manufacturer's protocols. HUVECs at passage 4 were seeded with a density of 8×105 cells in a gelatin-coated 60-mm dish, and CASMCs at passage 6 were seeded with a density of 3×105 cells in a 60-mm dish. After 24 hours, the cells were transfected with siRNA (final concentration of 50 nmol/L) using Lipofectamine 2000 (15 µL per dish) in a serum-free Opti-MEM for 6 hours, and the media were then changed with each complete growth medium.
Cav-1 overexpression in the HUVECs was performed 24 hours after siRNA transfection. The procedure of the plasmid vector preparation was described previously. 16 Plasmid DNA stocks of pmRmCherry (Clontech, Mountain View, CA) and mCherry-Caveolin-C-10 (Addgene, Cambridge, MA) were prepared in competent DH5-α cells (Intron) using the Plasmid Midi Kit (Qiagen, Valencia, CA). The stock concentration was adjusted to 1 mg/mL in nuclease-free water and stored at −20°C. Plasmid vector transfection in the HUVECs was performed using Lipofectamine 2000 according to the manufacturer's protocols. Plasmid DNA (2 µg/250 µL) and Lipofectamine (4 µL/250 µL) were individually diluted in Opti-MEM. After 5 minutes, the solutions were mixed and maintained at room temperature for 20 minutes. Mixtures were added to the HUVECs containing 2.5 mL of Opti-MEM and incubated at 37°C in 5% CO 2 for 6 hours.
Tube Formation Assay
Tube formation assay was performed using µ-slide angiogenesis (ibidi, Martinsried, Germany). Thereafter, 10-µL chilled Matrigel (BD Bioscience, San Jose, CA) was added in a precooled µ-slide well and allowed to solidify for 1 hour at 37°C. Twenty-four hours after plasmid vector transfection, the HUVECs were detached using TrypLETM Express Enzyme (Gibco, Grand Island, NY) and resuspended in an M199 medium containing 1% fetal bovine serum and 5-U/mL heparin. The cells (1×10 4 cells per well) were seeded onto solidified Matrigel in µ-slides and incubated at 37°C in 5% CO 2 for 4 hours. Tube formation images were captured using a light microscope at a magnification of ×40. Branches and loops of the tubes were counted using ImageJ software (National Institutes of Health, Bethesda, MD).
Apoptosis Assay
Twenty-four hours after transfection, the CASMCs were treated with staurosporine at 500 nmol/L for 24 hours. At 42 hours after siRNA transfection, the HUVECs were treated with staurosporine at 100 nmol/L for 6 hours. Thereafter, each cell was detached using TrypLE Express Enzyme and stained with annexin V-APC and 7-AAD (7-aminoactinomycin D) (BD Bioscience) according to the manufacturer's instructions. Flow cytometry analysis was performed within 1 hour using FACSCalibur (BD Bioscience).
Western Blotting
Cellular proteins were simultaneously prepared using other experimental procedures. Cell lysates were harvested in radioimmunoprecipitation assay buffer (Biosesang, Sungnam, Korea), supplemented with protease inhibitor cocktail (GenDEPOT, Barker, TX), and clarified via centrifugation at 13 200 rpm for 15 minutes. Protein samples were mixed with loading buffer, denatured at 10°C for 10 minutes, and then cooled at −4°C. Total protein samples were loaded on a 12% SDS-PAGE gel, and electrophoresis was performed. The proteins were transferred to nitrocellulose membranes (pore size, 0.45 µm). The membranes were then blocked with 5% nonfat milk for 1 hour at room temperature and incubated with the primary antibody in a blocking solution at 4°C overnight. Thereafter, the membranes were incubated with the secondary antibody for 2 hours at room temperature. The following antibodies were used: mouse monoclonal GAPDH (G-9) antibody (1:5000, Santacruz, Dallas, TX), mouse monoclonal cav-1 (7C8) antibody (1:1000; Invitrogen), rabbit polyclonal cleaved caspase-3 (Asp175) antibody (1:1000; Cell Signaling, Danvers, MA), rabbit polyclonal caspase-3 antibody (1:1000; Cell Signaling), anti-rabbit IgG HRP (horseradish peroxidase)-linked antibody (1:1000; Cell Signaling), and anti-mouse IgG HRP-linked antibody (1:1000; Cell Signaling).
Statistical Analysis
Differences in discrete variables between the groups were examined using the χ 2 , Fisher exact, or Mann-Whitney U test. Differences in continuous variables were examined using 1-way ANOVA, KruskalWallis test, or t test. In addition, independent factors for the degree of arterial remodeling were evaluated in patients with MMD using linear logistic regression. Adjustment variables in the multivariable regression models were selected from the potential outcome determinants that had a significant clinical relevance or showed P values of <0.20 in their associations with the outcome in the univariate analysis.
Before adjustment variable selection, variance inflation factors were calculated to check for possible multicollinearity. Significance levels were set at 2-tailed P values of <0.05. All statistical analyses were performed using commercially available software (STATA, version 13.1; Stata Corp, College Station, TX).
Results
During the study period, 98 adult patients with MMD were recruited. After excluding 11 patients who refused to be tested for the genetic mutation, 6 who showed poor cooperation during HR-MRI, and 4 whose HR-MRI findings could not be interpreted, 77 patients with MMD with 126 affected ICAs were included in the final analysis. Among them, 52 (67.5%) were women; 46 (59.7%) had a history of transient ischemic attack (n=17), ischemic stroke (n=25), and intracerebral hemorrhage (n=4); and 49 (63.6%) had bilateral ICA involvement. The average age was 46.4±13.4 years (range, 24-81). The patients' general characteristics, including age at the time of MMD diagnosis, vascular risk factors, and laboratory findings, are summarized in Table II in the online-only Data Supplement. Among the 17 controls with intracranial atherosclerotic stroke, 11 (64.7%) were women; their average age was 48.4±11.3 years (Table III in the online-only Data Supplement). The serum cav-1 levels were significantly lower in the patients with MMD than in the controls (0.47±0.29 versus 0.86±0.68; P=0.034).
The ICA diameters of the controls, patients with unilateral MMD, and patients with bilateral MMD are summarized in Figure 1 . The ICA diameters on the more severe side (2.35±1.02 mm) and the less severe side (2.68±0.81 mm) in patients with bilateral MMD and the affected side (2.73±0.97 mm) in patients with unilateral MMD were significantly smaller (P<0.05 for all comparisons) than the diameters of the asymptomatic ICAs in controls (3.84±0.42 mm). The ICA diameter on the unaffected side in patients with unilateral MMD (3.30±0.93 mm) was also significantly smaller than that in the controls (P=0.011). 
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The associations between the clinical, genetic, and biomarker factors and ICA diameters are shown in Table 1 
428).
When the cav-1 levels were categorized into quartiles, the level was positively associated with the ICA diameter (P<0.001). In the linear regression analysis, the cav-1 level was positively associated with the ICA diameter (coefficient, 0.984; P=0.001). Representative cases of the study findings are presented in Figure I in the online-only Data Supplement.
Based on these results, a multivariable logistic regression analysis was performed to determine the independent factors associated with negative arterial remodeling of the ICA in MMD. After adjusting for possible confounders (ie, age, male sex, clinical presentation, hypertension, diabetes mellitus, and dyslipidemia), the cav-1 level (log scale, coefficient, 0.637; P<0.001) remained independently associated with the distal ICA diameter (Table 2) .
To explore the factors associated with the serum levels of cav-1 further, the associations between the clinical and genetic factors and cav-1 levels were analyzed. Factors including age at MMD diagnosis, clinical presentation, RNF213 mutation, number of affected ICAs, and timing of blood sampling for cav-1 level measurement were not associated with the cav-1 level (Table 3) . Cav-1 indicates caveolin-1; and ICA, internal carotid artery. *Cav-1 levels were transformed to log scale owing to its log-normal distribution. Transfection with siRNA targeting cav-1 mRNA reduced cav-1 expression compared with the controls, whereas cav-1 vector transfection restored the cav-1 level in both the HUVECs and smooth muscle cells (Figure 2A) . One day after cav-1 vector transfection, the transfected vectors were expressed into the cells and overexpressed cav-1 localized in the cellular membrane ( Figure 2B ). Tube formation assay revealed a significant reduction in the angiogenic ability measured by branch and loop formation after cav-1 siRNA transfection and partial restoration with cav-1 vector transfection ( Figure 2C and 2D) . Apoptosis assays were performed using FACS (fluorescence-activated cell sorting) analysis to determine the association between the cav-1 level and apoptotic cell death. Cav-1 siRNA transfection significantly increased cellular apoptosis after staurosporine treatment in the HUVECs and CASMCs (Figure 3A and  3B) . In addition, expression of cleaved caspase-3-a marker of apoptosis-was also higher in the cav-1 repressed cells than in the control siRNA after staurosporine treatment in both cell types ( Figure 3C and 3D) . Further, overexpression of cav-1 in HUVECs suppressed apoptotic cell death and caspase-3 activation ( Figure II in the online-only Data Supplement).
Discussion
The major findings of this study are as follows: (1) a low serum cav-1 level was independently associated with negative remodeling of the distal ICA in adult patients with MMD, (2) clinical phenotype was associated with the ICA diameter in patients with MMD, and (3) lower cellular levels of cav-1 induced apoptosis of the vascular cells and impaired angiogenesis.
Although experimental studies have suggested the role of caveolin in angiogenesis, this study showed the role of cav-1 in intracranial artery remodeling in humans for the first time. In the present study, the serum cav-1 levels decreased in adult patients with angiographically proven MMD, and a low serum cav-1 level was associated with negative remodeling in these patients. Our in vitro experiments confirmed that decreased cellular cav-1 levels induce vascular cell apoptosis and impaired angiogenesis. These changes are consistent with the pathological features of negative arterial remodeling in MMD. 6 Vascular remodeling is an active process of structural alteration that involves changes in cell growth, cell death, cell migration, and production/degradation of the extracellular matrix. 9 The possible mechanisms underlying the association between cav-1 and vascular remodeling include as follows. First, cav-1 downregulation was associated with reduced capillary formation and increased pathological angiogenesis, whereas cav-1 overexpression accelerated capillary tube formation. 7, 8, 17 Second, cav-1 played a critical role in the recruitment of endothelial progenitor cells from the bone marrow in an ischemic hindlimb model. 18 Third, our present results showed that an enhanced apoptosis of the vascular cells related to cav-1 deficiency may be one of the mechanisms associated with the imaging and pathological findings of MMD (thinning of the stenotic segment). Lastly, remodeling is an adaptive process that occurs in response to long-term changes in hemodynamic conditions, and cav-1 may be involved in this process. However, the association of cav-1 with arterial remodeling has been controversial. 7, 8, 19 The degree of arterial remodeling may vary for different vascular systems. [20] [21] [22] The mechanisms of arterial remodeling may be complex, involving regional differences in cerebral blood flow (shear stress) and sympathetic vascular innervation. 20, 23 Our HR-MRI findings showed that the degree of negative remodeling of the distal ICA of patients with MMD was correlated with the symptomatology of patients with MMD in general; negative remodeling was more pronounced in symptomatic patients than in asymptomatic patients or in asymptomatic segments. The current monitoring method of the progression of MMD is serial luminal study to detect changes in stenosis degree and occurrence of contralateral involvement. No blood or imaging parameters are available for predicting clinical events in MMD. The results of our present and previous studies 14 suggest that the degree of negative remodeling and the presence of enhancement on HR-MRI could be used to monitor the disease progression in patients with MMD. We could not find a direct significant association between serum cav-1 and clinical events in patients with MMD. This could be attributable, at least in part, to the limited sample size. Further prospective studies with serial evaluations of cav-1 levels are needed.
At present, the mainstay of MMD treatment is surgical revascularization, which entails the possibility of perioperative ischemic complications and cerebral hyperperfusion syndrome. 24 Nonsurgical approaches to increase the serum cav-1 level could prevent or delay the progression of MMD and irreversible ischemic brain damage. Emerging evidence suggests cav-1 as a novel therapeutic target for cerebral ischemia. 25 In an analysis of the histological outcomes of cerebral ischemia, cav-1 deficiency was associated with a larger infarct and more apoptotic cell death, 26 whereas cav-1 peptide supplementation exerted a protective effect in a cardiac ischemia-reperfusion model. 27 In addition, depletion of cav-1 was associated with blood-brain barrier disruption after cerebral ischemia, and reexpression of cav-1 in cav-1 −/− mice restored tight junction protein expression and reduced matrix metalloproteinase proteolytic activity. 28 The results of our present study suggest that cav-1-enhancing strategies could be a possible treatment against MMD and method for constrictive remodeling.
This study had several limitations. First, it was a single-center study conducted at a tertiary referral hospital where bypass surgeries for MMD are actively performed. Furthermore, the RNF213 variant is a gene for MMD susceptibility only in East Asians. Therefore, the generalizability of the study results may be limited. In addition, by including patients with angiographically confirmed MMD evaluated using HR-MRI and tested for RNF213 polymorphism, data from only 77 patients with MMD were available for the analyses. The limited sample size in the present study may have underestimated the effect of other risk factors, that is, RNF213 mutation, on the plasma cav-1 level. Second, although patients with MMD were enrolled prospectively in the present study, HR-MRI was only performed once in each patient, and the serum cav-1 levels were measured only at a single point. Therefore, a direct causal relationship linking cav-1 with the progression of negative ICA remodeling in MMD could not be determined in this study. A future study with serial cav-1 level measurements and follow-up HR-MRI is warranted. Third, although authors collected blood samples from patients with acute ischemic stroke within 7 days of onset for control group, the serum cav-1 level could have been affected by interval between stroke onset and blood sampling. Fourth, only adult patients with MMD were included in this study. Epidemiological studies have reported an interesting bimodal age distribution in patients with MMD, with a peak in the pediatric group at ages from 5 to 14 years and a peak in the adult group at ages from 45 to 54 years. 29, 30 Further studies on children with MMD are needed to explore the possibility that they may have lower serum cav-1 levels than adult patients with MMD. Fifth, downregulation of cav-1 was reported to be associated with pathological angiogenesis in previous studies with cav-1 −/− mice. 17 The association between cav-1 and the degree of basal collateral formation in MMD remains to be explored. Sixth, flow dynamics could influence arterial remodeling, which was not investigated in the present study. We are planning to conduct magnetic resonance imaging-based flow dynamic studies together with HR-MRI in patients with MMD. Seventh, the pathomechanisms underlying the downregulation of cav-1 in MMD could not be identified in this study. Although we found an association between cav-1 and negative arterial remodeling in biological studies, more evidence on caveolin-associated smooth muscle cell migration and proliferation is needed. We are establishing vascular cells (both endothelial cells and smooth muscle cells) and primary endothelial progenitor cells derived from the induced pluripotent stem cells of patients with MMD to find definite evidence. Future studies that would evaluate the role of genetic interaction, circulating microRNA, and Src activation in cav-1 regulation are warranted. Finally, the normal distal ICA of patients with stroke was used as a control. This is because performing HR-MRI in healthy subjects is not practical. However, HR-MRI could preclude the existence of pathological features, including plaques, on the distal ICA segments of the controls.
In conclusion, our data indicate that negative remodeling may have clinical implications in that the degree of negative remodeling was associated with the symptomatology of the patients with MMD. Our clinical and experimental data also showed that cav-1 is involved in pathological negative arterial remodeling in adult MMD. Further research with serial monitoring of clinical events and cav-1 levels in relation to disease progression and development of novel therapeutic strategies targeting cav-1 to prevent MMD progression is warranted.
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